© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide considerations for regimen selection and emerging treatment options.
April 23rd 2021, 9:32pm
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
April 23rd 2021, 8:17pm
After a more than 35-year pursuit, the licensing of a gene therapy product for treating hemophilia may be available within 2 years.
April 15th 2021, 3:45pm
The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.
April 13th 2021, 3:18pm
After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.
April 9th 2021, 11:45am
Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.
April 4th 2021, 12:45pm
The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.
April 3rd 2021, 9:30am
Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
April 1st 2021, 12:40pm
Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
March 25th 2021, 1:30pm
Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.
March 24th 2021, 5:45pm
Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.